Jan. 11, 2022
NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, expanded on the information provided Monday at the H.C. Wainwright BioConnect Virtual Conference regarding the BriLife™ investigational vaccine for COVID-19.